Walmart Infant Formula Recall Issued Due to Risk of Metal Contamination

Perrigo Company is recalling more than 23,000 containers of Parent’s Choice baby formula, which was sold exclusively at Walmart, warning about a risk that metal pieces may be in the powder and harm infants.

The Walmart Parent’s Choice Advantage Infant Formula recall was posted to the FDA’s website on June 21, indicating containers may metal foreign material.

The recall came after a consumer reported finding metal pieces in one container of the formula. The manufacturer then determined one lot of Parent’s Choice Formula had the potential presence of “metal foreign matter” in a single lot, which could pose a serious risk for infants. However, no adverse events or injuries have been linked to the recalled baby formula to date.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The action impacts affects 23,388 35-ounce, 992-gram containers of Parent’s Choice Advantage Infant Formula Milk-Based Powder with Iron. Affected products have Lot Code C26EVFV with a “use by” date of February 26, 2021, printed on the bottom of the package.

The infant formula is advertised as “complete nutrition” for a baby’s first year and retails for $19.98. The recalled baby formula containers are sold exclusively at Walmart. The formula is used by adding the powder to water and shaking.

Foreign metal debris in baby powder could result in lacerations to the mouth, choking risks and damage to internal organs.

Customers who bought the product should immediately stop using the formula and return it to Walmart for a full refund. Consumers who have experienced problems with the formula or have health-related questions should contact Perrigo Consumer Affairs at (866) 629-6181.

Any injuries or side effects should be reported to the FDA MedWatch Adverse Event Reporting Program.

Written by: Martha Garcia

Health & Medical Research Writer

Martha Garcia is a health and medical research writer at AboutLawsuits.com with over 15 years of experience covering peer-reviewed studies and emerging public health risks. She previously led content strategy at The Blogsmith and contributes original reporting on drug safety, medical research, and health trends impacting consumers.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.
Plaintiffs involved in GLP-1 vision loss lawsuits are calling for the litigation to be consolidated in New Jersey federal court, and not be bundled with existing stomach paralysis litigation.